---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-004485"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2022-03-24T23:59:59+00:00"
generated_at: "2026-06-26T18:46:10.136421+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Surrozen reports full-year 2021 net loss of $47.3M; on track for Phase 1 starts in Q3 2022

## Summary
- FY2021 net loss $47.3M vs $20.4M in 2020; R&D expenses $35.5M.
- Cash and equivalents $137.8M as of Dec 31, 2021.
- Phase 1 trials for SZN-1326 (ulcerative colitis) and SZN-043 (alcoholic hepatitis) expected to start Q3 2022.
- Nominated SZN-413, a Fzd4 bi-specific antibody, for retinal vascular diseases including wet AMD.
- 2022 Annual Meeting set for June 7, 2022; record date April 11, 2022.

## SEC filing metadata
- accession: 0000950170-22-004485
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2022-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.08, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017022004485/0000950170-22-004485-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017022004485/srzn-20220321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-004485
- JSON: https://secwatch.observer/filing/0000950170-22-004485.json
- Plain text: https://secwatch.observer/filing/0000950170-22-004485.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.